Idursulfase - JCR Pharmaceuticals

Alternative Names: JR 141; Recombinant iduronate-2-sulfatase - JCR Pharmaceuticals

Latest Information Update: 29 Mar 2018

Price : ^*

* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

Originator JCR Pharmaceuticals
Class Iduronate sulfatases
Mechanism of Action Iduronate sulfatase replacements

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Phase I/II Mucopolysaccharidosis II

Most Recent Events

27 Mar 2018 JCR Pharmaceuticals announces intention to submit marketing application to Japan's Ministry of Health, Labour and Welfare for Mucopolysaccharidosis II (Hunter syndrome) in 2019
27 Mar 2018 The Ministry of Health, Labour and Welfare designates JR 141 for Mucopolysaccharidosis II (Hunter syndrome) under the SAKIGAKE Designation System in Japan
27 Mar 2018 JCR Pharmaceuticals plans a phase II/III trial for Mucopolysaccharidosis II in Brazil in 2018 (NCT03359213)

Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

Login with a username/password associated to an account with a valid subscription
Contact your organization’s admin about adding this content to your AdisInsight subscription
Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.